MPLT Stock Analysis: Buy, Sell, or Hold?
$28.64
-1.15 (-3.86%)
▼
5d:
+2.43%
30d:
-2.19%
90d:
+67.68%
HOLD
MODERATE Confidence
Analysis Updated: Jun 23, 2026 12:00 AM ET
Earnings: Aug 13, 2026
Get Alerted When MPLT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: MPLT shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: MPLT shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: MPLT is currently trading at $28.64, which is considered fair relative to its 30-day fair value range of $27.68 to $29.71.
Technical Outlook: Technically, MPLT is in a strong uptrend. Immediate support is located at $26.73, while resistance sits at $31.52. Short-term momentum is weak, with the stock down 3.9% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Implied Volatility is high (96th percentile), indicating expensive options premiums. This environment often favors selling options or covered calls to generate income. Wall Street analysts see significant upside, with an average price target of $39.20 (+36.9%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, MPLT is in a strong uptrend. Immediate support is located at $26.73, while resistance sits at $31.52. Short-term momentum is weak, with the stock down 3.9% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Implied Volatility is high (96th percentile), indicating expensive options premiums. This environment often favors selling options or covered calls to generate income. Wall Street analysts see significant upside, with an average price target of $39.20 (+36.9%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$27.68 -
$29.71
Company Quality Score
54/100
(HOLD)
Options IV Signal
96th percentile
(EVENT RISK)
Volume Confirmation
HIGH
Confidence Score
55.0%
All Signals
- NEUTRAL: Price in fair range
- BEARISH: Options expensive (IV 96th percentile)
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.9%)
- BULLISH: Trading 36.9% below Wall St target ($39.20)
Trading Range Analysis
30-Day Trading Range
$27.68 -
$29.71
Current vs Trading Range
FAIR
Expected Move (7 Days)
±$10.78
(37.6%)
Support & Resistance Levels
Support Level
$26.74
Resistance Level
$31.52
Current Trend
Strong Uptrend
Technical data as of
Jun 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-6.69
Wall Street Target
$39.20
(+36.9%)
Share & Embed Analysis
Last updated: June 23, 2026 8:21 PM ET
Data refreshes hourly during market hours. Next update: 9:21 PM
Data refreshes hourly during market hours. Next update: 9:21 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is MPLT showing a specific setup today?
Insider Activity (6 Months)
4
Buys
11
Sells
Net
INSIDERS SELLING
Recent Transactions
Robert C Malenka
SELL
736 shares
2026-02-24
Robert C Malenka
SELL
11264 shares
2026-02-23
George Pavlov
BUY
9920 shares
2026-02-20
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1022 | 67 BUY |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$197 | 61 BUY |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 57 HOLD |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
|
GPCR
Structure Therapeutics I… |
STRONG BUY
14 analysts |
$105 | 57 HOLD |